The first drug of its kind was just approved, and it could signal a massive change for pharmaceuticals
The drug contains the same active ingredient as Neupogen, or filgrastim, which logged 2014 worldwide sales of $1.2 billion for manufacturer Amgen.
The Food and Drug Administration (FDA) said it approved Zarxio for treating the same five conditions for which Neupogen is used.
The move had been expected after Zarxio, which is made by Novartis' generics unit Sandoz, won unanimous backing from an FDA panel in January.
(Reporting by Ben Hirschler. Editing by Jane Merriman)
- JPMorgan CEO Jamie Dimon told wealthy clients there's a chance the US is heading into 'something worse' than a recession, report says
- A 29-year-old woman found a mark on her head and was diagnosed with a fungal infection. It turned out to be invasive skin cancer.
- Here’s a list of stocks that can benefit from the festive season
- New Airtel and Reliance Jio prepaid plans compared
- Mobile accessories company Balaji Solutions files initial papers for public listing
- Ratan Tata launches Goodfellows which helps senior citizens make friends
- Rakesh Jhunjhunwala-backed Concord Biotech files for an IPO
- Ather 450X Gen 3 vs Ola S1 vs TVS iQube S – price, specs and features compared